Huntington Disease
Conditions
Brief summary
The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.
Interventions
None listed
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HD mutation carriers (\>36 CAG) * premanifest (total motor UHDRS \< 5) * estimated time to diagnosis between 3 and 10 years * adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years) * informed consent signed * with a social protection
Exclusion criteria
* MRI contraindication * pregnant and lactating women * People under guardianship, trusteeship, deprive of freedom
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in striatal volume | at 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SDMT -symbol digit modality test | at 1 years, at 2 years | measure the change of cognitive score for exposure caffeine groups |
| Stroop test | at 1 years, at 2 years | measure the change of cognitive score for exposure caffeine groups |
| Unified Huntington's Disease Rating Scale (UHDRS) | at 1 years, at 2 years | measure the change of motor scale for exposure caffeine groups |
| score at Epworth sleepiness scale | at 1 years, at 2 years | measure the change of sleepiness scale for exposure caffeine groups |
| MRI | at 1 years, at 2 years | measure the change of image of the whole brain and other deep gray nuclei atrophy |
| PBA (problem behaviors assessment) | at 1 years, at 2 years | the PBA is a semi structured clinical interview measuring the presence, severity and frequency of 11 key behavioural symptoms. measure the change score and subscores for apathy, obsessive-compulsive disorders, irritability, anxiety and depression, |
Countries
France
Outcome results
None listed